← All trials
NCT05050474
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 7, 2021
- Primary completion
- Aug 23, 2021
- Completion date
- Feb 3, 2022
- First posted
- Sep 20, 2021
- Last posted
- Sep 20, 2021
- Enrollment
- 43
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Livzon Pharmaceutical Group Inc.Lead sponsor
- Government of ChinaOverall official - principal investigator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.